BioNTech vs Pfizer Which Is More Lucrative?

BioNTech and Pfizer are two prominent companies at the forefront of developing the groundbreaking COVID-19 vaccine. As a result of their successful collaboration, both companies have witnessed a surge in their stock prices. BioNTech, a German biotechnology company, and Pfizer, an American pharmaceutical giant, have seen their stocks rise significantly as investors look to capitalize on the massive global demand for their vaccine. The competition between BioNTech and Pfizer stocks remains intense as both companies continue to innovate and expand their market presence.

BioNTech or Pfizer?

When comparing BioNTech and Pfizer, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between BioNTech and Pfizer.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. BioNTech has a dividend yield of -%, while Pfizer has a dividend yield of 6.4%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. BioNTech reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Pfizer reports a 5-year dividend growth of 4.08% year and a payout ratio of 221.76%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with BioNTech P/E ratio at -47.70 and Pfizer's P/E ratio at 34.91. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. BioNTech P/B ratio is 1.27 while Pfizer's P/B ratio is 1.61.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, BioNTech has seen a 5-year revenue growth of 27.23%, while Pfizer's is 0.13%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with BioNTech's ROE at -2.57% and Pfizer's ROE at 4.72%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $107.54 for BioNTech and $26.22 for Pfizer. Over the past year, BioNTech's prices ranged from $76.53 to $131.49, with a yearly change of 71.81%. Pfizer's prices fluctuated between $25.20 and $31.54, with a yearly change of 25.16%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.